The lack of specificity for tumor of most cytotoxic drugs in cancer therapy means that bone marrow suppression is a predictable phenomenon. How to anticipate the nadir of the drug-induced cytopenias, to monitor its progression, and deal with its consequences is described. In general, platelet and RBC transfusions are reserved for symptomatic relief, and granulocyte transfusions are rarely necessary.